Litigation Details for Bristol-Myers Squibb Company v. Sandoz Inc. (D. Del. 2017)
✉ Email this page to a colleague
Bristol-Myers Squibb Company v. Sandoz Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-04-10 |
| Court | District Court, D. Delaware | Date Terminated | 2019-05-07 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Defendant | Referred To | |
| Patents | 6,967,208; 9,326,945 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Bristol-Myers Squibb Company v. Sandoz Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-04-10 | 1 | expiration of U.S. Patent Nos. 6,967,208 (the “’208 patent”) and 9,326,945 (the “’945 patent”) (collectively…. This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 13. On November 22, 2005, the U.S. Patent and Trademark Office…copy of the ’208 patent is attached hereto as Exhibit A. The claims of the ’208 patent are valid, enforceable…, 2016, the U.S. Patent and Trademark Office duly and legally issued the ’945 patent, titled “Apixaban | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
